Anti-TIGIT antibodies and methods of use thereof
US11021537B2 · kind B2 · utility
1Cited by
13References
70Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 1, 2018 |
| Grant date | Jun 1, 2021 |
| Priority date | — |
| Expiry date | Apr 29, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.